Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study

BACKGROUND: The most effective treatment with immune checkpoint inhibitors (ICIs) is limited to the microsatellite instability high (MSI-H) subgroup of advanced colorectal cancer. ICIs are completely ineffective in microsatellite stabilized (MSS) patients with advanced colorectal cancer. Fruquintini...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Shoucheng, Chen, Rui, Duan, Ling, Li, Chunmei, Yang, Tianning, Wang, Jiankai, Zhao, Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186513/
https://www.ncbi.nlm.nih.gov/pubmed/37201046
http://dx.doi.org/10.21037/jgo-23-108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186513/
https://www.ncbi.nlm.nih.gov/pubmed/37201046
http://dx.doi.org/10.21037/jgo-23-108

Ejemplares similares